Stocksigma LogoStocksigma Logo

Sakar Healthcare Reports Strong Q2 FY27 Results Driven by Oncology Expansion

Sakar Healthcare reported robust Q2 FY27 performance, with operational revenue rising 52% YoY to INR 8,741.61 lakhs, EBITDA jumping 114% YoY to INR

Sakar Healthcare Reports Strong Q2 FY27 Results Driven by Oncology Expansion

Sakar Healthcare Ltd 路 Transcript 路 02 Nov 2026, 9:46 pm

Sakar Healthcare Reports Strong Q2 FY27 Results Driven by Oncology Expansion Sakar Healthcare reported robust Q2 FY27 performance, with operational revenue rising 52% YoY to INR 8,741.61 lakhs, EBITDA jumping 114% YoY to INR 2,434.53 lakhs (margin at 28% vs. 20%), and PAT surging 149% YoY to INR 1,130.69 lakhs. Management targets over 35% revenue growth and expects overall quarterly revenue to cross INR 100 crores from Q3. In oncology, API backward integration and upcoming global commercializations are projected to expand EBITDA margins toward 35% over the next two years.

Original exchange filing (PDF)

More announcements from Sakar Healthcare Ltd

All Sakar Healthcare Ltd announcements